Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Ohio State University
University of Texas
Washington University School of Medicine
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01862315
First received: May 20, 2013
Last updated: January 9, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)